Compare Alphabet Inc Class A (GOOGL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs 10X Genomics Inc — how do they compare? Alphabet Inc Class A trades at $355.62 (market cap $4.52T), while 10X Genomics Inc trades at $42.83 (market cap $5.81B). The key difference: Alphabet Inc Class A is far larger — about 778× 10X Genomics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | TXG | |
|---|---|---|
Market Cap | $4.52T | $5.81B |
Sector | Media | Health |
52-Week High | $402.62 | $45.80 |
52-Week Low | $182.97 | $11.34 |
Enterprise Value | $4.49T | $5.35B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $356.14, down 0.94% on the day, with strong technical support at $355 and resistance at $375. The stock shows bullish momentum in moving averages while oscillators remain neutral. Recent earnings consistently beat expectations, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 forecast. Revenue growth accelerated to $402.84 billion in 2025, with net income margins expanding to 32.8%.
Alphabet presents a compelling investment case with 85% analyst buy ratings and a $431.78 consensus price target representing 21% upside. Strong AI integration, YouTube price increases, and cloud partnerships drive growth, though regulatory scrutiny and tech sector volatility remain key risks. The company's robust cash flow generation and strategic investments position it well for sustained outperformance.
10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.
While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
